| Publication |
Sentence |
Publish Date |
Extraction Date |
Species |
| Lorna Piazzi, Angela Rampa, Alessandra Bisi, Silvia Gobbi, Federica Belluti, Andrea Cavalli, Manuela Bartolini, Vincenza Andrisano, Piero Valenti, Maurizio Recanatin. 3-(4-[[Benzyl(methyl)amino]methyl]phenyl)-6,7-dimethoxy-2H-2-chromenone (AP2238) inhibits both acetylcholinesterase and acetylcholinesterase-induced beta-amyloid aggregation: a dual function lead for Alzheimer's disease therapy. Journal of medicinal chemistry. vol 46. issue 12. 2003-07-11. PMID:12773032. |
3-(4-[[benzyl(methyl)amino]methyl]phenyl)-6,7-dimethoxy-2h-2-chromenone (ap2238) inhibits both acetylcholinesterase and acetylcholinesterase-induced beta-amyloid aggregation: a dual function lead for alzheimer's disease therapy. |
2003-07-11 |
2023-08-12 |
human |
| Laura A Volpicelli-Daley, Ellen G Duysen, Oksana Lockridge, Allan I Leve. Altered hippocampal muscarinic receptors in acetylcholinesterase-deficient mice. Annals of neurology. vol 53. issue 6. 2003-07-09. PMID:12783426. |
a primary therapeutic strategy for alzheimer's disease includes acetylcholinesterase (ache) inhibitors with the goal of enhancing cholinergic transmission. |
2003-07-09 |
2023-08-12 |
mouse |
| Stephen M Stahl, Jeffrey S Markowitz, Elane M Gutterman, George Papadopoulo. Co-use of donepezil and hypnotics among Alzheimer's disease patients living in the community. The Journal of clinical psychiatry. vol 64. issue 4. 2003-07-01. PMID:12716251. |
in clinical trials, sleep problems have been identified as side effects of donepezil, an acetylcholinesterase (ache)-inhibiting medication for the treatment of alzheimer's disease (ad). |
2003-07-01 |
2023-08-12 |
Not clear |
| Yukitaka Masuda, Atushi Kawamur. Acetylcholinesterase inhibitor (donepezil hydrochloride) reduces heart rate variability. Journal of cardiovascular pharmacology. vol 41 Suppl 1. 2003-06-27. PMID:12688400. |
an acetylcholinesterase inhibitor (donepezil hydrochloride) has recently been used for the treatment of senile dementia of alzheimer type. |
2003-06-27 |
2023-08-12 |
Not clear |
| Yukitaka Masuda, Atushi Kawamur. Acetylcholinesterase inhibitor (donepezil hydrochloride) reduces heart rate variability. Journal of cardiovascular pharmacology. vol 41 Suppl 1. 2003-06-27. PMID:12688400. |
the effect of this acetylcholinesterase inhibitor on the autonomic nervous control of the heart was investigated in 17 patients with senile dementia of alzheimer type. |
2003-06-27 |
2023-08-12 |
Not clear |
| J E Mintzer, P Kersha. The efficacy of galantamine in the treatment of Alzheimer's disease: comparison of patients previously treated with acetylcholinesterase inhibitors to patients with no prior exposure. International journal of geriatric psychiatry. vol 18. issue 4. 2003-06-19. PMID:12673604. |
the efficacy of galantamine in the treatment of alzheimer's disease: comparison of patients previously treated with acetylcholinesterase inhibitors to patients with no prior exposure. |
2003-06-19 |
2023-08-12 |
Not clear |
| J E Mintzer, P Kersha. The efficacy of galantamine in the treatment of Alzheimer's disease: comparison of patients previously treated with acetylcholinesterase inhibitors to patients with no prior exposure. International journal of geriatric psychiatry. vol 18. issue 4. 2003-06-19. PMID:12673604. |
acetylcholinesterase inhibitors (acheis) can provide benefits at the cognitive, behavioral, and functional levels to patients with alzheimer's disease (ad). |
2003-06-19 |
2023-08-12 |
Not clear |
| Ilkay Orhan, Salih Terzioglu, Bilge Sene. Alpha-onocerin: an acetylcholinesterase inhibitor from Lycopodium clavatum. Planta medica. vol 69. issue 3. 2003-06-16. PMID:12677532. |
in order to find new acetylcholinesterase inhibitors from natural sources which have therapeutic potential in the treatment of alzheimer's disease, the chloroform : methanol (1 : 1) extracts of five lycopodium species ( l. clavatum l., l. selago l., l. annotinum l., l. alpinum l., and l. complanatum ssp. |
2003-06-16 |
2023-08-12 |
Not clear |
| J Sáez-Valero, L R Fodero, M Sjögren, N Andreasen, S Amici, V Gallai, H Vanderstichele, E Vanmechelen, L Parnetti, K Blennow, D H Smal. Glycosylation of acetylcholinesterase and butyrylcholinesterase changes as a function of the duration of Alzheimer's disease. Journal of neuroscience research. vol 72. issue 4. 2003-06-06. PMID:12704813. |
glycosylation of acetylcholinesterase and butyrylcholinesterase changes as a function of the duration of alzheimer's disease. |
2003-06-06 |
2023-08-12 |
mouse |
| Iwona Kłoszewsk. [Acetylcholinesterase inhibitors--beyond Alzheimer's disease]. Psychiatria polska. vol 36. issue 6 Suppl. 2003-06-05. PMID:12647432. |
[acetylcholinesterase inhibitors--beyond alzheimer's disease]. |
2003-06-05 |
2023-08-12 |
Not clear |
| T Wobrock, P Retz-Junginger, W Retz, T Supprian, M Rösle. [Presentation and stability of cognitive and noncognitive symptom patterns in patients with Alzheimer's disease. Disease course over a two-year period under constant treatment conditions with rivastigmine]. Fortschritte der Neurologie-Psychiatrie. vol 71. issue 4. 2003-05-29. PMID:12677553. |
the course of behavioural and psychotic features of patients with alzheimer's disease treated with an inhibitor of the acetylcholinesterase (rivastigmine), and their association to cognitive impairment is presented in the study. |
2003-05-29 |
2023-08-12 |
Not clear |
| T Wobrock, P Retz-Junginger, W Retz, T Supprian, M Rösle. [Presentation and stability of cognitive and noncognitive symptom patterns in patients with Alzheimer's disease. Disease course over a two-year period under constant treatment conditions with rivastigmine]. Fortschritte der Neurologie-Psychiatrie. vol 71. issue 4. 2003-05-29. PMID:12677553. |
in addition to other studies of the course of alzheimer's disease we could demonstrate that distinct behavioural and psychotic symptoms may also present as independent factors in alzheimer patients under constant treatment conditions with an inhibitor of the acetylcholinesterase (rivastigmine). |
2003-05-29 |
2023-08-12 |
Not clear |
| Qin Zhao, Xi Can Tan. Effects of huperzine A on acetylcholinesterase isoforms in vitro: comparison with tacrine, donepezil, rivastigmine and physostigmine. European journal of pharmacology. vol 455. issue 2-3. 2003-05-16. PMID:12445575. |
these results suggest that the use of acetylcholinesterase inhibitors in treatment of alzheimer's disease must consider both form-specific and region-specific characteristics of acetylcholinesterase inhibition. |
2003-05-16 |
2023-08-12 |
rat |
| J J Buccafusco, W J Jackson, J D Stone, A V Terr. Sex dimorphisms in the cognitive-enhancing action of the Alzheimer's drug donepezil in aged Rhesus monkeys. Neuropharmacology. vol 44. issue 3. 2003-05-02. PMID:12604096. |
brain acetylcholinesterase has been targeted for the development of novel treatments for memory deficits associated with alzheimer's disease (ad) and other neurodegenerative disorders. |
2003-05-02 |
2023-08-12 |
human |
| Javier Sáez-Valero, Lisa R Fodero, Anthony R White, Colin J Barrow, David H Smal. Acetylcholinesterase is increased in mouse neuronal and astrocyte cultures after treatment with beta-amyloid peptides. Brain research. vol 965. issue 1-2. 2003-05-01. PMID:12591148. |
the cellular origin of the acetylcholinesterase (ache) associated with amyloid plaques in the alzheimer's disease (ad) brain is unknown. |
2003-05-01 |
2023-08-12 |
mouse |
| H Sugimot. Donepezil hydrochloride: a treatment drug for Alzheimer's disease. Chemical record (New York, N.Y.). vol 1. issue 1. 2003-04-22. PMID:11893059. |
the role of the cholinergic system with respect to cognitive deficits characteristic of alzheimer's disease (ad) has led to a number of studies focusing on the development of acetylcholinesterase (ache) inhibitors as a drug for treating this disease. |
2003-04-22 |
2023-08-12 |
Not clear |
| Krista L Lanctôt, Nathan Herrmann, Maysoon M LouLo. Correlates of response to acetylcholinesterase inhibitor therapy in Alzheimer's disease. Journal of psychiatry & neuroscience : JPN. vol 28. issue 1. 2003-04-17. PMID:12587847. |
correlates of response to acetylcholinesterase inhibitor therapy in alzheimer's disease. |
2003-04-17 |
2023-08-12 |
Not clear |
| Joana Barbosa Melo, Paula Agostinho, Catarina Resende Oliveir. Involvement of oxidative stress in the enhancement of acetylcholinesterase activity induced by amyloid beta-peptide. Neuroscience research. vol 45. issue 1. 2003-04-08. PMID:12507730. |
acetylcholinesterase (ache) activity is increased within and around amyloid plaques, which are present in alzheimer's disease (ad) patient's brain. |
2003-04-08 |
2023-08-12 |
Not clear |
| A Kur. Non-cognitive benefits of galantamine (Reminyl) treatment in vascular dementia. Acta neurologica Scandinavica. Supplementum. vol 178. 2003-04-02. PMID:12492788. |
acetylcholinesterase inhibitors (acheis), the treatment of choice in patients with alzheimer's disease (ad), are a potential treatment option for patients with vad. |
2003-04-02 |
2023-08-12 |
Not clear |
| Valtteri Kaasinen, Kjell Någren, Tarja Järvenpää, Anne Roivainen, Meixiang Yu, Vesa Oikonen, Timo Kurki, Juha O Rinn. Regional effects of donepezil and rivastigmine on cortical acetylcholinesterase activity in Alzheimer's disease. Journal of clinical psychopharmacology. vol 22. issue 6. 2003-03-31. PMID:12454562. |
regional effects of donepezil and rivastigmine on cortical acetylcholinesterase activity in alzheimer's disease. |
2003-03-31 |
2023-08-12 |
human |